Hospital
Walterboro Community Hospital, INC.
Walterboro Community Hospital, INC. was paid $11.78M by Medicaid between Jan 2018 and Dec 2024, across 168 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoWALTERBORO COMMUNITY HOSPITAL, INC.
WALTERBORO, SC 29488
WALTERBORO, SC 29488
33aNPI1376597997assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.78M
24GClaims378,306
24DCodes billed168
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#28 of 115
Median peer was paid$2.47M
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,513 | $1.58M | |
| 2019 | 45,898 | $1.26M | |
| 2020 | 52,890 | $1.27M | |
| 2021 | 64,187 | $1.68M | |
| 2022 | 63,046 | $2.23M | |
| 2023 | 52,915 | $2.33M | |
| 2024incomplete | 54,857 | $1.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 37,277 | 34,060 | $1.93M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 7.1% | 3,990 | 3,761 | $832K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.8% | 4,229 | 2,307 | $681K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 9,708 | 9,266 | $668K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.4% | 9,308 | 2,551 | $637K |
| 81001 | 5.4% | 17,791 | 15,782 | $635K | |
| 80053 | Comprehensive metabolic panel | 5.3% | 18,052 | 15,067 | $623K |
| 36415 | Collection of venous blood by venipuncture | 4.7% | 3,579 | 3,225 | $557K |
| 87070 | 4.3% | 4,728 | 4,591 | $506K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.1% | 19,868 | 17,619 | $367K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.6% | 7,385 | 7,090 | $305K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.2% | 4,463 | 4,210 | $258K |
156 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.0% | 1,718 | $234K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 7,339 | $223K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.7% | 5,239 | $204K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 940 | $138K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 2,477 | $131K |
| 11043 | 1.1% | 755 | $125K | |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 3,358 | $124K |
| 81025 | 1.0% | 9,637 | $123K | |
| 73562 | <1% | 1,924 | $114K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,131 | $98K |
| 73630 | <1% | 1,618 | $95K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,182 | $93K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,874 | $91K |
| 84702 | <1% | 1,149 | $84K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,248 | $83K |
| 73610 | <1% | 1,130 | $83K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 909 | $78K |
| 73030 | <1% | 1,426 | $77K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 819 | $76K |
| 99285 | Emergency room visit (most serious) | <1% | 4,063 | $73K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,225 | $66K |
| 73130 | <1% | 800 | $66K | |
| 81003 | <1% | 1,717 | $65K | |
| 87210 | <1% | 1,190 | $60K | |
| 87088 | <1% | 1,432 | $59K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,229 | $59K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,153 | $51K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 719 | $50K |
| J3490 | Unclassified drugs | <1% | 210 | $45K |
| 85027 | <1% | 24,224 | $42K | |
| 72050 | <1% | 424 | $40K | |
| 73110 | <1% | 499 | $37K | |
| 72100 | <1% | 1,024 | $36K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,533 | $34K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 259 | $33K |
| 74018 | <1% | 590 | $32K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,180 | $32K |
| 76830 | Ultrasound, transvaginal | <1% | 199 | $29K |
| 93971 | <1% | 446 | $28K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,075 | $28K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,090 | $27K |
| G0378 | Hospital observation service, per hour | <1% | 2,050 | $22K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 300 | $21K |
| 72110 | <1% | 161 | $20K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 727 | $20K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 901 | $19K |
| 84484 | <1% | 7,763 | $19K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,045 | $18K |
| 12001 | <1% | 50 | $17K | |
| 82731 | <1% | 73 | $15K | |
| 87807 | <1% | 1,416 | $15K | |
| 82077 | <1% | 747 | $14K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,268 | $13K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,787 | $13K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 58 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,307 | $12K |
| 82565 | <1% | 36 | $11K | |
| 74019 | <1% | 229 | $11K | |
| 73502 | <1% | 369 | $11K | |
| 76801 | <1% | 199 | $11K | |
| 97161 | <1% | 300 | $10K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,224 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,244 | $9K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 307 | $8K |
| 84703 | <1% | 821 | $8K | |
| 72070 | <1% | 117 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,558 | $7K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 25 | $7K |
| 80377 | <1% | 372 | $6K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 57 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 70 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,923 | $6K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,534 | $6K |
| 83735 | <1% | 2,246 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $5K |
| 73140 | <1% | 42 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 621 | $5K |
| 73080 | <1% | 50 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,680 | $5K |
| 96376 | <1% | 1,182 | $4K | |
| 76770 | <1% | 52 | $4K | |
| 97162 | <1% | 257 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,109 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 181 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,371 | $4K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 2,422 | $4K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 236 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,163 | $4K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 91 | $4K |
| 71250 | <1% | 40 | $4K | |
| 87077 | <1% | 100 | $3K | |
| 82805 | <1% | 522 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,909 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 161 | $3K |
| 93017 | <1% | 105 | $3K | |
| 80047 | <1% | 41 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $2K |
| 87485 | <1% | 269 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 784 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 52 | $2K |
| 76536 | <1% | 13 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $2K |
| 10060 | <1% | 28 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 827 | $2K |
| 72131 | <1% | 137 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $1K |
| 86900 | <1% | 912 | $1K | |
| 70486 | <1% | 25 | $1K | |
| 80061 | Lipid panel | <1% | 662 | $1K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 59 | $984.00 |
| 83880 | <1% | 2,295 | $953.05 | |
| 36000 | <1% | 222 | $595.52 | |
| 76642 | <1% | 16 | $590.54 | |
| 80320 | <1% | 266 | $547.88 | |
| 85378 | <1% | 555 | $512.64 | |
| 83605 | <1% | 1,513 | $470.94 | |
| 83690 | <1% | 4,746 | $461.30 | |
| 59020 | <1% | 1,986 | $454.42 | |
| 86850 | <1% | 400 | $401.32 | |
| 73620 | <1% | 14 | $314.79 | |
| 87040 | <1% | 1,391 | $279.12 | |
| 84439 | <1% | 171 | $267.42 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 63 | $210.72 |
| 97163 | <1% | 25 | $202.20 | |
| 85610 | <1% | 2,666 | $185.96 | |
| 90714 | <1% | 287 | $69.43 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 936 | $50.09 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 807 | $18.70 |
| 85730 | <1% | 2,412 | $7.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 353 | $0.00 |
| A9270 | Non-covered item or service | 0% | 3,618 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 496 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 490 | $0.00 |
| 86140 | 0% | 110 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 134 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 45 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 119 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 389 | $0.00 |
| 82728 | 0% | 26 | $0.00 | |
| 82150 | 0% | 13 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 26 | $0.00 |
| 97166 | 0% | 14 | $0.00 | |
| 70498 | 0% | 14 | $0.00 | |
| 86901 | 0% | 95 | $0.00 | |
| 70496 | 0% | 12 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,658 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 182 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 1,483 | $0.00 |
| 87186 | 0% | 87 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 73 | $0.00 |
| 80164 | 0% | 13 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 36 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 13 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 16 | $0.00 |
| 84100 | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBALL, CASSIE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Walterboro Community Hospital, INC. | Walterboro, SC | $949K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.